Jason P Rhodes
CIK 1577014 · President, CFO and Treasurer · last filed 2026-08-17
Jason P Rhodes is a President, CFO and Treasurer who has filed 54 SEC Form 4 insider transactions across 5 companies since 2013. The most recent filing shows the insider sold $65.2M of DYN on Aug 17, 2026. Across all open-market trades the lifetime net is −$173.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $27.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DYN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
400 TECHNOLOGY SQUARE, 4TH FLOOR
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DYN | Director | 567,358 | $16.04 | $9.10M | -$148.46M | 20 | 2026-08-17 |
| Generation Bio Co. (GBIO) Delisted | Director | 0 | $5.34 | $0 | -$18.24M | 14 | 2026-02-09 |
| REPL | Director | 946,000 | $19.34 | $18.30M | -$2.69M | 11 | 2022-04-05 |
| Disc Medicine, Inc. (GMTX) Delisted | Director | — | $13.50 | — | $0 | 1 | 2021-10-06 |
| Epizyme, Inc. (EPZM) Delisted | President, CFO and Treasurer | 138,000 | $1.47 | $202.9K | -$4.54M | 8 | 2014-09-24 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| DYN | Atlas Venture Fund XI, L.P. See footnote |
567,358 | 100.0% | 2026-08-17 |
| Total | 567,358 | |||
| GBIO | Direct | 0 | — | 2026-02-09 |
| Atlas Venture Opportunity Fund I, L.P. See Footnote |
0 | — | 2026-02-09 | |
| Total | 0 | |||
| REPL | Atlas Venture Fund X, L.P. See footnote |
946,000 | 100.0% | 2021-01-28 |
| Total | 946,000 |
Recent Filings
54 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-17 | DYN | Sell (S)10b5-1 Plan adopted Jul 13, 2026 |
−2,586,928 | -$65.18M | EDGAR |
| 2026-07-08 | DYN | Sell (S)10b5-1 Plan adopted Mar 19, 2026 |
−777,451 | -$17.86M | EDGAR |
| 2026-06-26 | DYN | Sell (S)10b5-1 Plan adopted Mar 19, 2026 |
−267,760 | -$5.65M | EDGAR |
| 2026-06-09 | DYN | Grant (A) | — | $0 | EDGAR |
| 2026-05-06 | DYN | Sell (S)10b5-1 Plan adopted Mar 19, 2026 |
−106,723 | -$1.94M | EDGAR |
| 2026-04-27 | DYN | Sell (S)10b5-1 Plan adopted Mar 19, 2026 |
−384,549 | -$7.10M | EDGAR |
| 2026-04-22 | DYN | Sell (S)10b5-1 Plan adopted Mar 19, 2026 |
−834,302 | -$16.48M | EDGAR |
| 2026-02-09 | Generation Bio Co. (GBIO) Delisted | Mixed | −827,946 | $0 | EDGAR |
| 2025-06-06 | Generation Bio Co. (GBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-06-03 | DYN | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).